iRhythm Technologies, a $3.48 billion cardiac monitoring technology company, announced that board member Mojdeh Poul will not seek re-election at the upcoming annual stockholders meeting. Poul’s decision aligns with her recent appointment as President and Chief Executive Officer of Integra LifeSciences Holdings Corporation. According to an 8-K filing with the Securities and Exchange Commission, her term will conclude on the date of the next annual meeting. Poul confirmed that her decision was not due to any disagreements with iRhythm Technologies or its management. The company has not yet announced a successor or any changes to the board’s composition following her departure.
Investors are closely monitoring the transition, as iRhythm continues its strategic focus on medical technology. The company has experienced a stock increase of over 25 percent in the past six months, with analysts highlighting strong financial performance, including an 18.4 percent revenue rise year-over-year, reaching $147.5 million. Additionally, analysts at Needham and Oppenheimer have raised their price targets for iRhythm to $112 and $120, respectively. Recent developments, such as updates to its corporate governance policies and a technology licensing agreement with BioIntelliSense, reflect the company’s ongoing initiatives in cardiac monitoring solutions.
